8th Aug 2013 07:00
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Notice of Results
8 August 2013- Deltex Medical Group plc (AIM: DEMG), the global leader in oesophageal Doppler monitoring ("ODM"), which measures blood flow in real time enabling fluid level optimisation to enhance recovery after surgery and in intensive care, will be announcing its Interim Results for the six-month period ended 30 June 2013 on Tuesday, 10 September 2013.
The management will be hosting a presentation for analysts on the day of results at 13:00pm at the offices of Newgate Threadneedle, 5th floor, 33 King William Street, London EC4R 9AS. Analysts who wish to attend the presentation should register their interest with Heather Armstrong, contactable at [email protected] or 020 7653 9841.
For further information, please contact:-
Deltex Medical Group plc | 01243 774 837 |
Nigel Keen, Chairman | |
Ewan Phillips, Chief Executive | |
Paul Mitchell, Finance Director | |
Nominated Adviser & Broker | |
Arden Partners plc | 020 7614 5900 |
Chris Hardie | |
Financial Public Relations | |
Newgate Threadneedle | 020 7653 9850 |
Graham Herring | |
Caroline Evans-Jones | |
Heather Armstrong |
About Deltex
Deltex Medical manufactures and markets CardioQ-ODMÔ Oesophageal Doppler Monitoring ('ODM') systems. ODM is the only therapy to measure blood flow in the central circulation in real time. Minimally invasive, easy to set up and quick to focus, the technology generates a low-frequency ultrasound signal, which is highly sensitive to changes in flow and measures them immediately. Randomised, controlled trials using Doppler have demonstrated that early fluid management intervention will reduce post-operative complications, reduce intensive care admissions, and reduce the length of hospital stay.
The CardioQ-ODM has two distinct established clinical applications: firstly, to guide fluid management during surgery and secondly, to monitor cardiac output in critical care settings.
Related Shares:
Deltex Medical